bluebird bio, Inc. (NASDAQ:BLUE) Q4 2023 Earnings Conference Call March 26, 2024 8:00 AM ET
Company Participants
Courtney O'Leary - Director of IR
Andrew Obenshain - CEO
Tom Klima - Chief Commercial and Operating Officer
Chris Krawtschuk - CFO
Conference Call Participants
Jason Gerberry - Bank of America Securities
Danielle Brill - Raymond James
Jack Allen - Baird
Gena Wang - Barclays
Eric Joseph - JPMorgan
Mani Foroohar - Leerink
Jeffrey Hung - Morgan Stanley
Salveen Richter - Goldman Sachs
Sami Corwin - William Blair
Operator
Good day, and welcome to bluebird bio Fourth Quarter and 2023 Annual Results Conference Call.
At this time all participants are in a listen-only mode. [Operator Instructions] Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Courtney O'Leary, Investor Relations. Please go ahead.
Courtney O'Leary
Good morning, everyone and thank you for joining our fourth quarter and 2023 annual results call today. My name is Courtney O'Leary, Director of Investor Relations at bluebird bio.
Before we begin, let me review our Safe Harbor statement. Today's discussion contains statements that are forward-looking under the Private Securities Litigation Reform Act of 1995, including expectations regarding our future financial results and financial position, in addition to statements of the company's plans, expectations or intentions regarding regulatory progress, commercialization plans and business operations. Such statements are based on current expectations and assumptions that are subject to risks and uncertainties and involve a number of risk factors that could cause actual results to differ materially from projected results. A description of these risks is contained in our filings with the SEC, which are available on the Investor Relations section of our website, www.bluebirdbio.com.
On today's call, Andrew Obenshain, bluebird bio's CEO, will provide a general corporate update. And then Tom Klima, Chief Commercial and Operating Officer, will discuss progress on the commercial launches of LYFGENIA, ZYNTEGLO and SKYSONA. And finally, Chris Krawtschuk, Chief Financial Officer will provide a financial update before opening the call up for Q&A.
With that, I will turn it over to Andrew.
Andrew Obenshain
Thanks, Courtney and thank you, everyone, for joining our call this morning as we provide an update on our fourth quarter and 2023 annual results and discuss our strategic outlook and planned milestones for 2024.
Earlier this morning, we put out an 8-K announcing that we will be restating financial information for 2022 and for the first three quarters of 2023, and that we've submitted an extension on our 10-K filing. We now anticipate filing the 10-K inclusive of that restatement no later than April 16. Importantly, the restatement does not impact our cash position or revenue. Chris will discuss this in greater detail later in the call.